114 related articles for article (PubMed ID: 8747521)
1. Localization of a calcium-dependent epitope to the amino terminal region of the Gla domain of human factor IX.
Cheung WF; Stafford DW; Sugo T
Thromb Res; 1996 Jan; 81(1):65-73. PubMed ID: 8747521
[TBL] [Abstract][Full Text] [Related]
2. Characterization of gamma-carboxyglutamic acid residue 21 of human factor IX.
Wolberg AS; Li L; Cheung WF; Hamaguchi N; Pedersen LG; Stafford DW
Biochemistry; 1996 Aug; 35(32):10321-7. PubMed ID: 8756687
[TBL] [Abstract][Full Text] [Related]
3. Localization of a metal-dependent epitope to the amino terminal residues 33-40 of human factor IX.
Cheung WF; Wolberg AS; Stafford DW; Smith KJ
Thromb Res; 1995 Dec; 80(5):419-27. PubMed ID: 8588203
[TBL] [Abstract][Full Text] [Related]
4. Identification of residues in the Gla-domain of human factor IX involved in the binding to conformation specific antibodies.
Wojcik EG; Cheung WF; van den Berg M; van der Linden IK; Stafford DW; Bertina RM
Biochim Biophys Acta; 1998 Jan; 1382(1):91-101. PubMed ID: 9507074
[TBL] [Abstract][Full Text] [Related]
5. Crystal structure of the calcium-stabilized human factor IX Gla domain bound to a conformation-specific anti-factor IX antibody.
Huang M; Furie BC; Furie B
J Biol Chem; 2004 Apr; 279(14):14338-46. PubMed ID: 14722079
[TBL] [Abstract][Full Text] [Related]
6. Localization of an epitope of a calcium-dependent monoclonal antibody to the N-terminal region of the Gla domain of human factor VII.
Cheung WF; Stafford DW
Thromb Res; 1995 Jul; 79(2):199-206. PubMed ID: 7676406
[TBL] [Abstract][Full Text] [Related]
7. Discontinuous residues of factor IX constitute a surface for binding the anti-factor IX monoclonal antibody A-5.
Chang YJ; Wu HL; Hsu YC; Hamaguchi N; Shi GY; Shen MC; Lin SW
Thromb Res; 2003; 111(4-5):293-9. PubMed ID: 14693178
[TBL] [Abstract][Full Text] [Related]
8. gamma-Carboxyglutamic acids 36 and 40 do not contribute to human factor IX function.
Gillis S; Furie BC; Furie B; Patel H; Huberty MC; Switzer M; Foster WB; Scoble HA; Bond MD
Protein Sci; 1997 Jan; 6(1):185-96. PubMed ID: 9007991
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal antibody (VII-M31) to bovine factor VII: a specific epitope in the gamma-carboxyglutamic acid domain.
Higashi S; Kawabata S; Nishimura H; Funasaki H; Ohyama S; Miyamoto S; Funatsu A; Iwanaga S
J Biochem; 1990 Oct; 108(4):654-62. PubMed ID: 1705545
[TBL] [Abstract][Full Text] [Related]
10. The binding of human factor IX to endothelial cells is mediated by residues 3-11.
Cheung WF; Hamaguchi N; Smith KJ; Stafford DW
J Biol Chem; 1992 Oct; 267(29):20529-31. PubMed ID: 1400370
[TBL] [Abstract][Full Text] [Related]
11. Structure of the calcium ion-bound gamma-carboxyglutamic acid-rich domain of factor IX.
Freedman SJ; Furie BC; Furie B; Baleja JD
Biochemistry; 1995 Sep; 34(38):12126-37. PubMed ID: 7547952
[TBL] [Abstract][Full Text] [Related]
12. Structural requirements for Ca2+ binding to the gamma-carboxyglutamic acid and epidermal growth factor-like regions of factor IX. Studies using intact domains isolated from controlled proteolytic digests of bovine factor IX.
Astermark J; Björk I; Ohlin AK; Stenflo J
J Biol Chem; 1991 Feb; 266(4):2430-7. PubMed ID: 1989994
[TBL] [Abstract][Full Text] [Related]
13. Factor IX Zutphen: a Cys18-->Arg mutation results in formation of a heterodimer with alpha 1-microglobulin and the inability to form a calcium-induced conformation.
Wojcik EG; van den Berg M; van der Linden IK; Poort SR; Cupers R; Bertina RM
Biochem J; 1995 Nov; 311 ( Pt 3)(Pt 3):753-9. PubMed ID: 7487929
[TBL] [Abstract][Full Text] [Related]
14. Membrane binding properties of the factor IX gamma-carboxyglutamic acid-rich domain prepared by chemical synthesis.
Jacobs M; Freedman SJ; Furie BC; Furie B
J Biol Chem; 1994 Oct; 269(41):25494-501. PubMed ID: 7929250
[TBL] [Abstract][Full Text] [Related]
15. The endothelial cell binding determinant of human factor IX resides in the gamma-carboxyglutamic acid domain.
Toomey JR; Smith KJ; Roberts HR; Stafford DW
Biochemistry; 1992 Feb; 31(6):1806-8. PubMed ID: 1310619
[TBL] [Abstract][Full Text] [Related]
16. Functional mapping of anti-factor IX inhibitors developed in patients with severe hemophilia B.
Christophe OD; Lenting PJ; Cherel G; Boon-Spijker M; Lavergne JM; Boertjes R; Briquel ME; de Goede-Bolder A; Goudemand J; Gaillard S; d'Oiron R; Meyer D; Mertens K
Blood; 2001 Sep; 98(5):1416-23. PubMed ID: 11520790
[TBL] [Abstract][Full Text] [Related]
17. Role of the propeptide and gamma-glutamic acid domain of factor IX for in vitro carboxylation by the vitamin K-dependent carboxylase.
Stanley TB; Wu SM; Houben RJ; Mutucumarana VP; Stafford DW
Biochemistry; 1998 Sep; 37(38):13262-8. PubMed ID: 9748333
[TBL] [Abstract][Full Text] [Related]
18. An anti-EGF monoclonal antibody that detects intramolecular communication in factor IX.
Persson KE; Knobe KE; Stenflo J
Biochem Biophys Res Commun; 2001 Sep; 286(5):1039-44. PubMed ID: 11527405
[TBL] [Abstract][Full Text] [Related]
19. The N-terminal epidermal growth factor-like domain of coagulation factor IX. Probing its functions in the activation of factor IX and factor X with a monoclonal antibody.
Persson KE; Villoutreix BO; Thämlitz AM; Knobe KE; Stenflo J
J Biol Chem; 2002 Sep; 277(38):35616-24. PubMed ID: 12105230
[TBL] [Abstract][Full Text] [Related]
20. Derivatives of blood coagulation factor IX contain a high affinity Ca2+-binding site that lacks gamma-carboxyglutamic acid.
Morita T; Isaacs BS; Esmon CT; Johnson AE
J Biol Chem; 1984 May; 259(9):5698-704. PubMed ID: 6425296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
